Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra ...

Kezar Life Sciences (NASDAQ:KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

With Kezar Life Sciences’ lupus plans up in the air while the company investigates patient deaths, Concentra Biosciences has ...

The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...

On Thursday, Kezar Life Sciences Inc (KZR) stock saw a decline, ending the day at $0.82 which represents a decrease of $-0.07 or -7.87% from the prior close of $0.89. The stock opened at $0.86 and ...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Renowned higher education researcher Dr. Adrianna Kezar will be visiting campus on November 7-8 We invite staff and faculty ...

Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to ...

Oct 17 (Reuters) - Kezar Life Sciences (KZR.O), opens new tab said on Thursday it would terminate its mid-stage trial studying its experimental drug in patients with active lupus nephritis and ...